このエピソードについて
Prescient Therapeutics chief executive James McDonnell talked with Proactive about the company’s share purchase plan, which is targeting up to $7 million to support the ongoing Phase 2a clinical program for its lead cancer therapy, PTX-100.
The funds will help Prescient Therapeutics continue progressing PTX-100 through the study, with an important near-term milestone expected later in 2026. The company is currently running Phase 2a trial sites in Australia, the United States and Italy, with France expected to join the program in the early part of next year.
The study has enrolled 28 patients. A dose optimisation committee will begin reviewing progress once there are 10 evaluable patients in each of the study’s two arms. Prescient Therapeutics expects that review to take place towards the end of 2026.
The committee will assess safety and help define a dose that could be taken forward into the next stage of the clinical program.
Prescient Therapeutics expects further visibility on the study’s progress around November or December as the dose optimisation review approaches.
Visit Proactive’s YouTube channel for more interviews and company updates. Don’t forget to like the video, subscribe to the channel and enable notifications for future content.
The funds will help Prescient Therapeutics continue progressing PTX-100 through the study, with an important near-term milestone expected later in 2026. The company is currently running Phase 2a trial sites in Australia, the United States and Italy, with France expected to join the program in the early part of next year.
The study has enrolled 28 patients. A dose optimisation committee will begin reviewing progress once there are 10 evaluable patients in each of the study’s two arms. Prescient Therapeutics expects that review to take place towards the end of 2026.
The committee will assess safety and help define a dose that could be taken forward into the next stage of the clinical program.
Prescient Therapeutics expects further visibility on the study’s progress around November or December as the dose optimisation review approaches.
Visit Proactive’s YouTube channel for more interviews and company updates. Don’t forget to like the video, subscribe to the channel and enable notifications for future content.
英語
アメリカ合衆国
文字起こし 🔗
Are you the producer of this podcast?
Add a podcast transcript
Need Audio-to-Text?
Transcribe with Listen411 in Just 60 Seconds
このポッドキャストの他のエピソード
MetaOptics Technologies CFO Alex Chu joined Steve Darling from Proactive to discuss the company’s latest milestone as it expands its presence in the United States. The company has officially commenced trading of its American Depositary Shares (ADSs) on the OTCQX market under the ticker symbol MOTLY…
HANetf Product Specialist Harry Halewood joined Steve Darling from Proactive to explain how option income strategies, including covered calls, can be used to generate ongoing income while maintaining exposure to the potential returns of equity markets.
Halewood explained that a covered call strate…
ReconAfrica CEO Brian Reinsborough joined Steve Darling from Proactive to provide an update on the company’s expanding African energy portfolio, highlighting progress at its KW1X discovery well in Namibia, encouraging exploration results in Angola, and ongoing seismic work offshore Gabon.
Reinsbor…
BrenX CEO Nir Brenmiller joined Steve Darling from Proactive to announce that the company has entered into a definitive real estate sale and purchase agreement to acquire approximately 10,872 square meters of industrial land and photovoltaic infrastructure adjacent to its operating solar facility i…
Tiziana Life Sciences CEO Ivor Elrifi joined Steve Darling from Proactive to announce an important milestone in the company’s neuroimmunology pipeline, with the first three participants receiving their initial doses of intranasal foralumab in the Phase 2a Healey ALS MyMatch BANYAN clinical trial.
…
免責: このページに埋め込まれているポッドキャストとアートワークは Proactive からのものであり、その所有者の所有物であり、Listen Notes, Inc. と提携または承認されていません。
